ImmuneOnco Biopharmaceuticals on its HK$319 Million IPO

brandonc1 on October 13, 2023

immune Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.

CapitalXchange® is a registered service mark of Cooley LLP.

Disclaimer
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, Cooley SG LLP, Cooley HK or any other Cooley entity (collectively referred to as “Cooley”). By reviewing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice, and it is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep it confidential. This content may be considered Attorney Advertising and is subject to our legal notices. The views expressed on the blog do not constitute legal advice, and are the views of the authors only and not those of Cooley.

Legal notices & privacy policy

Categories

Tags

Archives

ImmuneOnco Biopharmaceuticals on its HK$319 Million IPO

Related